About
Our Vision
Our Mission
Core Values
Management Team
Board of Directors
Scientific Advisory Board
Investors
Pipeline
Pipeline Overview
ES104
ES102
ES101
ES002
ES014
ES009
ES004
ES005
ES008
ES019
ES028
Science
Immuno-Oncology Approach
Translational Medicine
Proprietary Discovery Platform
Clinical Development
Partnering
Partnering Strategy
Our Partners
Contact Us
News
Press Release
Media Reports
Careers
Our Values
Our Leadership Commitment
Our Talent Strategy
Working at Elpiscience
Our Story
Join Us
Contact Us
Home
About
Pipeline
Science
Partnering
News
Careers
Contact Us
Our Vision
Our Mission
Core Values
Team
Investors
Pipeline Overview
Immuno-Oncology Approach
Translational Medicine
Proprietary Discovery Platform
Clinical Development
CMC Expertise and State-of-the-Art Manufacturing
Partnering Strategy
Our Partners
Contact Us
Press Release
Media Reports
Our Values
Our Leadership Commitment
Our Talent Strategy
Working at Elpiscience
Our Story
Join Us
Contact Us
Welcome to Leave Your Message
The United States
News
Press Release
Media Reports
October 21, 2021
Elpiscience Builds Out Global Pipeline with CD39 Focus
Learn More
May 14, 2021
Kept an Ocean Away from Its Scientific Advisors, Shanghai's Elpiscience Keeps up the Clinical Progress, Refuels for its I/O Pipeline
Learn More
October 27, 2021
How China Turned the Tables on Biopharma's Global Dealmaking
Learn More
October 28, 2021
What’s next for CRISPR & gene therapy
Learn More
<
1
>
Home
About
Our Vision
Our Mission
Core Values
Management Team
Board of Directors
Scientific Advisory Board
Investors
Pipeline
Pipeline Overview
ES104
ES102
ES101
ES002
ES014
ES009
ES004
ES005
ES008
ES019
ES028
Science
Immuno-Oncology Approach
Translational Medicine
Proprietary Discovery Platform
Clinical Development
Partnering
Partnering Strategy
Our Partners
Contact Us
News
Press Release
Media Reports
Careers
Our Values
Our Leadership Commitment
Our Talent Strategy
Working at Elpiscience
Our Story
Join Us
Contact Us